Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Longitudinal changes in self-reported walking ability in multiple sclerosis.
Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers.
Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis.
The visual pathway as a model to understand brain damage in multiple sclerosis.
Myelin-derived lipids modulate macrophage activity by liver x receptor activation.
Adherence to Interferon β-1b Treatment in Patients with Multiple Sclerosis in Spain.
Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis.
Autophagy in immunity: Implications in etiology of autoimmune/autoinflammatory diseases.
Only low frequency event-related EEG activity is compromised in multiple sclerosis: insights from an independent component clustering analysis.
Common mechanisms in neurodegeneration and neuroinflammation: a BrainNet Europe gene expression microarray study.
Residential Distance to High-voltage Power Lines and Risk of Neurodegenerative Diseases: a Danish Population-based Case-Control Study.
Paracaspase MALT1 Deficiency Protects Mice from Autoimmune-Mediated Demyelination.
ISENTRESS® prescribing information
Pathology of multiple sclerosis: where do we stand?
Bee Venom Acupuncture Alleviates Experimental Autoimmune Encephalomyelitis by Upregulating Regulatory T Cells and Suppressing Th1 and Th17 Responses.
Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review.
2014 multiple sclerosis therapeutic update.
Clinical experience of natalizumab in Crohn's disease patients in a restricted distribution program.
Myelin Basic Protein and a Multiple Sclerosis-related MBP-peptide Bind to Oligonucleotides.
Perivascular spaces in MS patients at 7 Tesla MRI: A marker of neurodegeneration?
[Compensatory mechanisms in multiple sclerosis(review)].
Discovery of A-971432, an Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonists for the Potential Treatment of Neurodegenerative Disorders.
Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen.
Application of laser radiation and magnetostimulation in therapy of patients with multiple sclerosis.
VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses.

Pages